Prostaglandin E2 hastens oviductal transport of equine embryos.
The hypothesis that treatment of pregnant mares with prostaglandin E2 (PGE2) hastens the oviductal transport of equine embryos was tested by treating bred mares with PGE2 on Day 3 after ovulation and subsequently measuring the rate of hastened oviductal transport (estimated by the uterine embryo recovery rate on Day 4 after ovulation). In a preliminary, noncontrolled experiment, oviductal transport was apparently not hastened after intramuscular, intrauterine, or intraperitoneal PGE2 administration to bred mares (0/6, 0/3, and 0/3 mares, respectively). Oviductal transport appeared to be hastened in 1/13 mares after a single intraoviductal administration of PGE2, and in 2/2 mares after continuous intraoviductal administration of PGE2. In a subsequent, controlled experiment, treatment with a continuous intraoviductal infusion of PGE2 hastened oviductal transport in significantly more (p less than 0.01) mares versus a continuous intraoviductal infusion of vehicle or no treatment (6/11 vs. 0/11 or 0/11 mares, respectively). Unfertilized oocytes and oviductal masses were also recovered from mare uteri after continuous intraoviductal PGE2 administration, but were not recovered after vehicle administration or no treatment. These results support the hypothesis that PGE2 treatment hastens the oviductal transport of equine embryos, and suggest a role for embryonic PGE2 in the initiation of selective oviductal transport in the mare.
Weber
J A
JA
Department of Animal and Veterinary Science, University of Idaho, Moscow 83843.
Freeman
D A
DA
Vanderwall
D K
DK
Woods
G L
GL
D000818:Animals; D015232:Dinoprostone / Q000494:pharmacology*; D004333:Drug Administration Routes; D004622:Embryo, Mammalian / Q000502:physiology; D005260:Female; D006736:Horses / Q000502:physiology*; D010057:Oviducts / Q000187:drug effects* / Q000502:physiology; D011247:Pregnancy
D015232:Dinoprostone